Description
AvatropagAvatrombopag Maleate INN
20
Ziska Pharmaceuticals Ltd.
Kaliakoir, Gazipur, Bangladesh
Manufactured by:
Composition:
Each film coated tablet contains Avatrombopag Maleate INN eqv. to Avatrombopag 20 mg.
Pharmacology:
Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that
stimulates proliferation and differentiation of megakaryocytes from bone marrow
progenitor cells, resulting in an increased production of platelets. The median time to
maximal concentration (Tmax) occurred at 5 to 6 hours post-dose. Avatrombopag has
an estimated mean volume of distribution (%CV) of 180 L (25%). Avatrombopag is
greater than 96% bound to human plasma proteins. The mean plasma elimination
half-life (%CV) of avatrombopag is approximately 19 hours (19%). The mean (%CV) of
the clearance of avatrombopag is estimated to be 6.9 L/hr (29%). Avatrombopag is
primarily metabolized by cytochrome P450 CYP2C9 and CYP3A4. Fecal excretion
accounted for 88% of the administered dose, with 34% of the dose excreted as
unchanged avatrombopag. Only 6% of the administered dose was found in urine.
Indications:
Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD): It is
indicated for the treatment of thrombocytopenia in adult patients with chronic liver
disease who are scheduled to undergo a procedure.
Treatment of Thrombocytopenia in Patients with Chronic Immune
Thrombocytopenia (ITP): It is indicated for the treatment of thrombocytopenia in adult
patients with chronic immune thrombocytopenia who have had an insufficient response
to a previous treatment.
Dosage and administration: Recommended Dosage for Patients with Chronic Liver
Disease: Table 1: Recommended Dose and Duration in Patients with Chronic Liver
Disease Scheduled to Undergo a Procedure
Reviews
There are no reviews yet.